Paul Goddard, Ph.D.
Dr. Goddard has guided companies at all stages of development over his more than 30 years in the life science industry. Dr. Goddard has held senior executive positions at several major pharmaceutical and biotechnology companies, including Neurex Corporation, Elan Pharmaceuticals and SmithKline Beecham Corporation. Following the acquisition of Neurex by Elan Corporation, he was appointed Chief Executive Officer of Elan Pharmaceuticals, the largest operating division of Elan, with operations in ten countries, focusing on acute care, pain management, and neurological disease. Dr. Goddard also served as Chairman and Chief Executive Officer of ARYx Therapeutics.
Dr. Goddard served as lead director on the board of Onyx Pharmaceuticals (a subsidiary of Amgen) and on the boards of several other companies including Adolor Corporation, A.P. Pharma, Molecular Devices and Xenoport. Dr. Goddard completed his Ph.D. in the area of Etiology and Pathophysiology of colon cancer at St. Mary's Hospital, University of London.